Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Gary Manko

Internal Medicine Reisterstown, MD Medical Doctor

NPI 1588612139 CMS profile 162636

750 Main St Ste 205, Reisterstown, MD 21136

Open in the dashboard

General payments

$4,638

258 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Gary Manko of Reisterstown, MD is reported in the CMS Open Payments database as having received $4,638 across 258 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $81 1
2022 General $704 29
2021 General $1,217 64
2020 General $752 48
2019 General $1,883 116

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gary Manko
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gary Manko were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gary Manko Internal Medicine median Middle half National median
2019 $1,883 $159 $48–$570 $163
2020 $752 $119 $33–$402 $114
2021 $1,217 $135 $37–$521 $132
2022 $704 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $81 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $652 52 payments
  2. Sanofi-Aventis U.S. LLC $430 11 payments
  3. Merck Sharp & Dohme Corporation $377 18 payments
  4. Lilly USA, LLC $375 26 payments
  5. Amarin Pharma Inc. $326 12 payments
  6. AstraZeneca Pharmaceuticals LP $287 20 payments
  7. Amgen Inc. $276 15 payments
  8. AbbVie, Inc. $271 13 payments
  9. Pfizer Inc. $257 14 payments
  10. GlaxoSmithKline, LLC. $228 9 payments
  11. Other $1,159 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $4,638 258 payments
Products named General payments · program years 2019–2024
  1. Ozempic $399 36 payments
  2. RYBELSUS $276 23 payments
  3. FARXIGA $270 19 payments
  4. JARDIANCE $267 17 payments
  5. STEGLATRO $244 13 payments
  6. TRULICITY $243 16 payments
  7. SOLIQUA 100/33 $209 4 payments
  8. UBRELVY $204 10 payments
  9. TRELEGY ELLIPTA $200 7 payments
  10. MYRBETRIQ $190 12 payments
  11. Other $4,221 255 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

249

Median for Internal Medicine: 777

Drug cost

$23,238

Median for Internal Medicine: $73,373

Branded share of claims

8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 20 $19,891
Clonidine Generic 11 $1,131
Olmesartan Medoxomil Generic 26 $725
Rosuvastatin Calcium Generic 32 $289
Levothyroxine Sodium Generic 25 $253
Atorvastatin Calcium Generic 31 $235
Amlodipine Besylate Generic 21 $156
Lisinopril Generic 22 $145
Losartan Potassium Generic 22 $140
Allopurinol Generic 12 $125

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$16,266

Of which drugs: $2,026

Medicare patients

128

Average age 74

Services billed

345

66 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 51%
Depression 28%
Ischemic heart disease 27%
Cancer 23%
Chronic kidney disease 19%
Atrial fibrillation 18%
Osteoporosis 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

258 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record